TY - JOUR
T1 - Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial
AU - Chudy-Onwugaje, Kenechukwu
AU - Huang, Wen Yi
AU - Su, L. Joseph
AU - Purdue, Mark P.
AU - Johnson, Christine C.
AU - Wang, Lingxiao
AU - Katki, Hormuzd A.
AU - Barry, Kathryn Hughes
AU - Berndt, Sonja I.
N1 - Publisher Copyright:
© 2021 American Cancer Society. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Background: Studying the differential impact of aspirin and other nonsteroidal anti-inflammatory drugs across the stages of colorectal neoplasia from early adenoma to cancer is critical for understanding the benefits of these widely used drugs. Methods: With 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. With multivariable-adjusted models, odds ratio (ORs) and 95% confidence intervals (CIs) for adenoma incidence and recurrence and hazard ratios (HRs) and 95% CIs for incident CRC were determined. Results: The authors observed a significantly reduced risk of incident adenoma with ibuprofen use (≥30 vs <4 pills per month: OR, 0.76 [95% CI, 0.60-0.95]; Ptrend =.04), particularly advanced adenoma (OR, 0.48 [95% CI, 0.28-0.83]; Ptrend =.005). Among those with a previous adenoma detected through screening, aspirin use was associated with a decreased risk of advanced recurrent adenoma (≥30 vs <4 pills per month: OR, 0.56 [95% CI, 0.36-0.87]; Ptrend = 0.006). Both aspirin (HR, 0.88 [95% CI, 0.81-0.96]; Ptrend <.0001) and ibuprofen use (HR, 0.81 [95% CI, 0.70-0.93); Ptrend = 0.003) ≥30 versus <4 pills per month were significantly associated with reduced CRC risk. Conclusions: In this large prospective study with long-term follow-up, a beneficial role for not only aspirin, but also ibuprofen, in preventing advanced adenoma and curbing progression to recurrence and cancer among older adults was observed.
AB - Background: Studying the differential impact of aspirin and other nonsteroidal anti-inflammatory drugs across the stages of colorectal neoplasia from early adenoma to cancer is critical for understanding the benefits of these widely used drugs. Methods: With 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. With multivariable-adjusted models, odds ratio (ORs) and 95% confidence intervals (CIs) for adenoma incidence and recurrence and hazard ratios (HRs) and 95% CIs for incident CRC were determined. Results: The authors observed a significantly reduced risk of incident adenoma with ibuprofen use (≥30 vs <4 pills per month: OR, 0.76 [95% CI, 0.60-0.95]; Ptrend =.04), particularly advanced adenoma (OR, 0.48 [95% CI, 0.28-0.83]; Ptrend =.005). Among those with a previous adenoma detected through screening, aspirin use was associated with a decreased risk of advanced recurrent adenoma (≥30 vs <4 pills per month: OR, 0.56 [95% CI, 0.36-0.87]; Ptrend = 0.006). Both aspirin (HR, 0.88 [95% CI, 0.81-0.96]; Ptrend <.0001) and ibuprofen use (HR, 0.81 [95% CI, 0.70-0.93); Ptrend = 0.003) ≥30 versus <4 pills per month were significantly associated with reduced CRC risk. Conclusions: In this large prospective study with long-term follow-up, a beneficial role for not only aspirin, but also ibuprofen, in preventing advanced adenoma and curbing progression to recurrence and cancer among older adults was observed.
KW - aspirin
KW - colorectal cancer
KW - ibuprofen
KW - incident adenoma
KW - recurrent adenoma
UR - http://www.scopus.com/inward/record.url?scp=85105505516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105505516&partnerID=8YFLogxK
U2 - 10.1002/cncr.33623
DO - 10.1002/cncr.33623
M3 - Article
C2 - 33974712
AN - SCOPUS:85105505516
SN - 0008-543X
VL - 127
SP - 3145
EP - 3155
JO - Cancer
JF - Cancer
IS - 17
ER -